Skip to Content
Merck
CN
  • Modeling G2019S-LRRK2 Sporadic Parkinson's Disease in 3D Midbrain Organoids.

Modeling G2019S-LRRK2 Sporadic Parkinson's Disease in 3D Midbrain Organoids.

Stem cell reports (2019-02-26)
Hongwon Kim, Hyeok Ju Park, Hwan Choi, Yujung Chang, Hanseul Park, Jaein Shin, Junyeop Kim, Christopher J Lengner, Yong Kyu Lee, Jongpil Kim
ABSTRACT

Recent advances in generating three-dimensional (3D) organoid systems from stem cells offer new possibilities for disease modeling and drug screening because organoids can recapitulate aspects of in vivo architecture and physiology. In this study, we generate isogenic 3D midbrain organoids with or without a Parkinson's disease-associated LRRK2 G2019S mutation to study the pathogenic mechanisms associated with LRRK2 mutation. We demonstrate that these organoids can recapitulate the 3D pathological hallmarks observed in patients with LRRK2-associated sporadic Parkinson's disease. Importantly, analysis of the protein-protein interaction network in mutant organoids revealed that TXNIP, a thiol-oxidoreductase, is functionally important in the development of LRRK2-associated Parkinson's disease in a 3D environment. These results provide proof of principle for the utility of 3D organoid-based modeling of sporadic Parkinson's disease in advancing therapeutic discovery.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-EEA1 Antibody, from rabbit, purified by affinity chromatography
Sigma-Aldrich
Anti-Neurogenin-2 Antibody, Chemicon®, from rabbit
Sigma-Aldrich
Anti-β-Tubulin III antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
Sigma-Aldrich
Anti-TRA-1-60 Antibody, clone TRA-1-60, clone TRA-1-60, Chemicon®, from mouse
Sigma-Aldrich
Anti-Dopamine Transporter Antibody, NT, clone DAT-Nt, culture supernatant, clone DAT-Nt, Chemicon®